Nomorobo Fights Back Against Social Network Tracking and Data Thieves

NEW YORK, NY—(Marketwired – April 05, 2018) – Nomorobo, one of the most popular services for blocking robocalls and protecting consumers from telemarketers, is expanding its protection beyond voice calls and spam texts. In response to recent revelations that various companies are deceptively using social media sites to track consumers' online behavior, Nomorobo has released version 2.5 of its app which provides web tracking protection as well as an online ad blocker. With the release of this version of the Nomorobo app, users will be better protected from potential scammers, data thieves, and virus infections that prey on unsuspecting Americans.

“Our privacy is more at risk than ever before. It seems that without our knowledge, some companies have been wildly overstepping the bounds of acceptable use of consumers' online behavior. Using shady loopholes, they are practically tracking our every move and digging into some of our most private actions,” says Aaron Foss, Founder of Nomorobo. “This is a privacy invasion that goes beyond pesky robocallers. At Nomorobo, our goal is to protect our users from all types of scams and invasions of privacy. Consumers need better protection. Installing the newly updated Nomorobo app on your phone is a powerful first step.”

Web advertisements are not only annoying but, increasingly, they are being used to track users everywhere they go online. These ads are often targeted, intrusive, and can even carry malware and viruses. But now, with the simple flip of a switch and at no additional cost, the Nomorobo app virtually eliminates all types of ads and privacy invading trackers. In addition, since fewer resources are being used, pages on mobile devices load faster, data usage is reduced, and battery life is extended.

These enhanced privacy protection features are joined by Nomorobo's award winning robocall blocking service. To date, Nomorobo has stopped over 600 million illegal robocalls from reaching consumers. As the winner of the 2013 U.S. Federal Trade Commission Robocall Challenge, the company remains the most trusted name in telemarketer fraud protection. The service's unique technology is able to accurately differentiate between illegal, unwanted robocalls and legitimate, important automated calls from providers like doctors, pharmacies, and public safety organizations. Over 1.6 million people trust Nomorobo every day to protect their phones.

Nomorobo was designed from the ground up to eliminate irritating robocalls as painlessly as possible. For mobile phones, after the app is installed and configured, robocalls are identified or automatically blocked. Nomorobo doesn't require access to customers' contacts, call logs, or even their phone number. Nomorobo has a 14–day free trial and costs $1.99 per month after that, which can be cancelled from within the app at any time in accordance with other terms and conditions. For landline phones, the service is supported by most of the leading VoIP carriers at no additional charge.

To learn more about Nomorobo, visit www.nomorobo.com.

About Nomorobo
Nomorobo is a cloud–based service that effectively blocks illegal robocalls from reaching consumers' phones. Nomorobo employs a unique, FTC–approved technology that analyzes incoming calls and rapidly detects robocallers, telemarketers, and scammers. Legitimate calls come through normally, but illegal robocalls are stopped before they have a chance to bother the consumer. Nomorobo's service has been integrated into many of the nation's top VoIP phone carriers and mobile apps including Charter Spectrum, Verizon FiOS, Ooma, Sonic, Burner and more.

Advanzeon Solutions, Inc.'s Wholly-Owned Subsidiary, Pharmacy Value Management Solutions, Inc., Enters Into Agreement With Interstate Specialty Marketing, Inc.

TAMPA, FL—(Marketwired – April 05, 2018) – Advanzeon Solutions, Inc. (OTCBB: CHCR) (“Advanzeon”) announced today that, through its wholly–owned subsidiary, Pharmacy Value Management Solutions, Inc. (“PVMS”) (collectively, the “Company”), it has entered into an Agreement with Interstate Specialty Marketing, Inc. (“ISM”). Founded in 1983, ISM began as a traditional life insurance marketing company providing traditional life products. ISM creates its own innovative products and provides administrative systems — both of which are unparalleled in the industry. Today, they are a nationally–based financial sales and services company, successfully marketing their own proprietary product as well as other high–end healthcare products through various distribution channels. ISM and ISM Administrators (“ISMA”) provide oversight and administrative services to two very active associations – the American Association of Private Employees and the American Association of Government Employees (“Associations”). ISMA services tens of thousands of policy/certificate holders and clients.The Agreement between the Company and ISM provides for the Company to make available the SleepMaster Solutions™ (“SMS”) Sleep Apnea Program (the “Program”) as a benefit of the Associations, on a going–forward basis (see: www.americanassociations.org). The Agreement is effective immediately.

Gary Hendricks, ISM's CEO, stated, “We are very pleased about entering into this Agreement with PVMS, and excited about adding the SleepMaster Solutions™ program to our Associations. Sleep apnea is a chronic disease that is rising in prevalence in the U.S., with millions of Americans being affected every day. Our Association members have come to rely on the benefits and services offered and our commitment to providing only top–quality programs. We are confident that the SleepMaster Solutions™ Program complements our pledge to that commitment and is an invaluable addition. It is our belief that we will see a significant interest and growth in membership, due to its addition.”

Clark A. Marcus, the Company's Chairman and CEO, added, “We are proud to offer our SleepMaster Solutions™ Program to the Association's portfolio of benefits. The services and innovative products provided by Interstate Specialty Marketing and ISMA have set them apart as a premier leader in their respective fields. We look forward to our relationship with ISM.”

About Advanzeon Solutions, Inc.

Established in 1969, Advanzeon, through its subsidiaries, owns and operates the nation's most complete sleep apnea program known as SleepMaster Solutions™ (the “Program”). Headquartered in Tampa, Florida, the Company's Program is available in all fifty states, Washington D.C. and Puerto Rico. The Program focuses on personalized attention, flexibility, a commitment to high–quality services and innovative approaches that address both the specific needs of clients and changing healthcare industry demands. For more information, visit our website at www.advanzeon.com.

Forward–Looking Statements

This press release contains forward–looking statements that are subject to risks and uncertainties. These forward–looking statements include information about possible or assumed future results of our business, financial condition, liquidity, results of operations, plans and objectives. In some cases, you may identify forward–looking statements by words such as “may,” “should,” “plan,” “intend,” “potential,” “continue,” “believe,” “expect,” “predict,” “anticipate” and “estimate,” the negative of these words or other comparable words. These statements are only predictions. One should not place undue reliance on these forward–looking statements. The forward–looking statements are qualified by their terms and/or important factors, many of which are outside the Company's control, involve a number of risks, uncertainties and other factors that could cause actual results and events to differ materially from the statements made. The forward–looking statements are based on the Company's beliefs, assumptions and expectations of our future performance, taking into account information currently available to the Company. These beliefs, assumptions and expectations can change as a result of many possible events or factors, not all of which are known to the Company. Neither the Company nor any other person assumes responsibility for the accuracy or completeness of these statements. The Company will update the information in this press release only to the extent required under applicable securities laws. If a change occurs, the Company's business, financial condition, liquidity and results of operations may vary materially from those expressed in the aforementioned forward–looking statements.

NanoVibronix Announces Instrumed Surgical as its Exclusive Canadian Distributor for UroShield(TM)

ELMSFORD, NY—(Marketwired – April 05, 2018) – NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced it has signed Instrumed Surgical of Mississauga, Ontario, Canada as its exclusive distributor for UroShield™ products in the Canada. Instrumed Surgical is a privately held Canadian company focusing on the surgical and endoscopy segments of the Canadian medical products market. Instrumed Surgical has been selling medical products in Canada since its inception in 1987 and is both ISO 13485 certified as well as Health Canada approved.

UroShield™ is an ultrasound–based product that is designed to prevent bacterial colonization and biofilm on indwelling urinary catheters and increase antibiotic efficacy, ultimately reducing the incidence of catheter–associated urinary tract infections (CAUTI). UroShield is also intended to decrease pain and discomfort associated with urinary catheter use. CAUTIs are a significant contributor to healthcare–associated UTIs and have been associated with increased morbidity, mortality, hospital cost, and length of stay. In the U.S. alone, it is estimated that over 13,000 deaths per year are attributable to CAUTIs. UroShield™ is Health Canada approved.

Leonard Ineson, CEO of Instrumed Surgical, commented, “CAUTI is a major cause of patient mortality, and there is growing concern over antimicrobial resistance to urinary pathogens. We believe UroShield™ has the potential to not only save lives, but also decrease the use of antibiotics by lowering infection rates. We look forward to rapidly rolling out UroShield across Canada and believe there will be strong support from the Canadian medical community due to both the patient and economic benefits of the product.”

Brian Murphy, Chief Executive Officer of NanoVibronix Inc., commented, “Instrumed Surgical is one of the premier medical device distributors in Canada, with over 3 decades of experience and an impressive sales network that covers all the major hospitals across Canada. This partnership follows our recent announcement of a UK distributor and represents another major milestone in our global rollout strategy.”

About NanoVibronix
NanoVibronix Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, NY with research and development in Nesher, Israel, that is focused on developing medical devices utilizing its proprietary and patented low intensity surface acoustic wave technology. The company's technology allows for the creation of low–frequency ultrasound waves that can be utilized for a variety of medical applications, including the disruption of biofilms and bacteria colonization, as well as providing pain relief. The devices can be administered at home, without the assistance of medical professionals. The company's primary products include PainShield®, UroShield™ and WoundShield™. Additional information about the company is available at: www.nanovibronix.com.

Forward–looking Statements
This press release contains “forward–looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward–looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward–looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10–K and its Quarterly Reports on Form 10–Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward–looking statements as a result of new information, future events or otherwise..